CCI
PTCT icon

Columbus Circle Investors’s PTC Therapeutics PTCT Stock Holding History

Columbus Circle Investors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,640
Closed -$247K – 305
2017
Q2 		$232K Sell
12,640
-145,940
-92% -$1.97M ﹤0.01% 242
2017
Q1 		$1.56M Buy
158,580
+49,316
+45% +$597K 0.02% 232
2016
Q4 		$1.19M Buy
109,264
+69,532
+175% +$729K 0.02% 233
2016
Q3 		$557K Buy
+39,732
New +$323K 0.01% 266
2016
Q1 		– Sell
-883,228
Closed -$28.6M – 301
2015
Q4 		$28.6M Buy
883,228
+410,653
+87% +$12.1M 0.23% 100
2015
Q3 		$12.6M Buy
472,575
+8,374
+2% +$358K 0.1% 170
2015
Q2 		$22.3M Sell
464,201
-13,842
-3% -$808K 0.16% 156
2015
Q1 		$29.1M Sell
478,043
-149,329
-24% -$9.11M 0.2% 116
2014
Q4 		$32.5M Buy
627,372
+608,587
+3,240% +$26.8M 0.23% 101
2014
Q3 		$827K Sell
18,785
-46,519
-71% -$1.46M 0.01% 237
2014
Q2 		$1.71M Buy
+65,304
New +$1.4M 0.01% 254
2013
Q4 		– Sell
-224,010
Closed -$4.81M – 330
2013
Q3 		$4.81M Buy
+224,010
New +$3.89M 0.03% 258

Other funds holding PTCT

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Columbus Circle Investors's PTCT Position: Q3 2017 in Review

Columbus Circle Investors sold out of PTC Therapeutics (PTCT) in Q3 2017, closing a stake of 12,640 shares — an estimated $247K sold.

Columbus Circle Investors first reported a position in PTCT in Q3 2013 and held it in 12 quarters. The position peaked at $32.5M in Q4 2014. 129 funds tracked by Wall St. Rank hold PTCT as of Q3 2017.

  • Columbus Circle Investors reported no remaining PTC Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 12,640 PTC Therapeutics shares in Q3 2017, an estimated $247K.
  • Columbus Circle Investors first reported a position in PTC Therapeutics in Q3 2013 and held it in 12 quarters.
  • Columbus Circle Investors's PTC Therapeutics position peaked at $32.5M in Q4 2014.
  • 129 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2017.

Based on Columbus Circle Investors's 13F filing for Q3 2017, filed 8 Nov 2017.